MEDIA

Latest News

RS Research Announces Poster Presentation at the ESMO TAT 2023 Congress

RS Research, a clinical-stage biotechnology start-up developing smart nanomedicines for targeted chemotherapy, announced the acceptance of a poster presentation at the European Society for Medical Oncology Targeted Anticancer Therapies (ESMO TAT) 2023 Congress on 6-8 March in Paris – France, being known as “The Home of Phase I in Oncology”. […]

Read More

RS Research has raised $12 Million

Clinical-stage biotechnology start-up developing smart nanomedicines in oncology raised $12 Million at Series-A Round with investors GEN, OneLife and Eczacıbaşı Momentum. This funding will help the company gain speed in the clinical development of its portfolio as well as become […]

Read More

Major Investment in Turkish Biotechnology Start-up

Technology focused venture capital fund ACT Venture Partners, whose main investor is European Investment Fund, has invested 1.1 million Euros in nanomedicine start-up RS Research. The company began developing drug candidates with improved efficacy and reduced side effect […]

Read More
Brand Guideline & Files